secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2026-05-11T20:09:10+00:00
Accession:  0001601485-26-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 net loss $11.8M ($0.65/sh); Phase 2 DFS readout mid-2026; cash runway into Q4
--------------------------------------------------------------------------------

- Q1 net loss $11.8M ($0.65/sh) vs $11.2M ($0.87/sh) YoY; R&D $6.8M, G&A $3.8M.
- Cash $14.9M at Mar 31; raised $13M via ATM in Q1-Q2; expected runway into Q4 2026.
- Phase 2 AMPLIFY-7P primary DFS analysis for ELI-002 7P in PDAC expected mid-2026; fewer events observed.
- Company remains blinded; after DFS readout, plans End-of-Phase 2 FDA meeting for Phase 3 design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/0001601485-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/eltx-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001601485-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer